• • Some potential solutions exist. Some potential solutions exist.
• • Not widely known. Not widely known.
• • • Synthesize flexible and applicable paradigm. Synthesize flexible and applicable paradigm.
• • Reach consensus. Reach consensus.
• • Offer accepted, practical approach to CV development. Offer accepted, practical approach to CV development.
• • Not "lowering the bar" for vaccine approval. Not "lowering the bar" for vaccine approval. • Dose and schedule are not determined through escalation based on toxicity.
• CV usually do not get metabolized: no need for conventional pharmakokinetics.
• Many CV are designed to address one tumor type: no need for mixed tumor trials for target selection.
• Conventional short-term response criteria (e.g. RECIST) are not well applicable to CV and historical control comparisons on RR are not useful: proof-of-principle endpoints should reflect biologic activity including immunogenicity.
• Standard trial designs lack flexibility to translate new learning into late-phase trials. Validation needs proof-of-correlation between outcome and biological marker in single-arm or randomized studies.
Proposed Development Paradigm for Cancer Vaccines Proposed Development Paradigm for Cancer Vaccines
• Associated with the therapeutic intervention (e.g. immune response):
Validation needs randomized trial showing that intervention-induced surrogate correlates with outcome.
Molecular response as a surrogate endpoint
• CV are expected to work best in minimal residual disease (MRD) populations.
• Molecular markers allowing uniform assessment of MRD and the impact of a vaccine on the target disease can function as a measure of biological and/or clinical activity.
• Examples:
CML: well-defined canonical chromosomal abnormality (BCR-ABL) detectable by RT-PCR AML: multiple heterogeneous chromosomal abnormalities not present in all patients, requiring an array of markers to determine biological activity in a non-selected group of patients.
